StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

TScan Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -1695.1%. For fiscal 2025 it was -1315.4%, against -4787.7% the year before. The highest annual figure on record is -444.0% in fiscal 2023.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1315.4%+3472.3
FY2024Dec 31, 2024-4787.7%−4343.7
FY2023Dec 31, 2023-444.0%+48.3
FY2022Dec 31, 2022-492.3%−12.7
FY2021Dec 31, 2021-479.6%+1938.1
FY2020Dec 31, 2020-2417.8%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2901.3%−1644.7
Q1 FY2026Mar 31, 2026-2967.3%−1297.6
Q4 FY2025Dec 31, 2025-929.4%+4591.2
Q3 FY2025Sep 30, 2025-1475.6%+1634.2
Q2 FY2025Jun 30, 2025-1256.6%+5108.0
Q1 FY2025Mar 31, 2025-1669.7%+3873.2
Q4 FY2024Dec 31, 2024-5520.6%−5224.4
Q3 FY2024Sep 30, 2024-3109.8%−2473.1
Q2 FY2024Jun 30, 2024-6364.6%−5582.8
Q1 FY2024Mar 31, 2024-5542.9%−5208.6
Q4 FY2023Dec 31, 2023-296.2%+306.4
Q3 FY2023Sep 30, 2023-636.7%−143.7
Q2 FY2023Jun 30, 2023-781.8%−405.9
Q1 FY2023Mar 31, 2023-334.3%+200.7
Q4 FY2022Dec 31, 2022-602.6%−104.9
Q3 FY2022Sep 30, 2022-493.0%+163.8
Q2 FY2022Jun 30, 2022-375.9%−0.9
Q1 FY2022Mar 31, 2022-535.0%−144.4
Q4 FY2021Dec 31, 2021-497.6%+484.8
Q3 FY2021Sep 30, 2021-656.8%+1816.0
Q2 FY2021Jun 30, 2021-375.0%–
Q1 FY2021Mar 31, 2021-390.6%–
Q4 FY2020Dec 31, 2020-982.4%–
Q3 FY2020Sep 30, 2020-2472.8%–

More TScan Therapeutics figures

See a number that looks wrong?